Upon approval, Rocket has been awarded a priority review voucher, which currently fetch around $200m on the secondary market.
Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years. This week, his role in a clinical trial has culminated in the first-ever U.S. Food and Drug ...
With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit. | Rocket ...
Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential ...
Gene therapy represents one of medicine’s most ambitious attempts to treat disease at its root cause by altering the genetic code itself. The approach works by recovering the functions of critical ...
1d
Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I Kids
Rocket Pharmaceuticals (NASDAQ:RCKT) said the U.S. Food and Drug Administration has granted accelerated approval to KRESLADI ...
An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and ...
The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring. | The company is working ...
Parent advocate Mrs Dharmisha Stezaly speaking at ELRIG in March 2026 set out how early treatment with the gene therapy ...
Five-year clinical study results show this revolutionary one-time treatment allowed 94% of patients to stop routine factor IX prophylaxis DETROIT, March 23, 2026 /PRNewswire/ -- The Barbara Ann ...
The Greater Philadelphia Business Coalition on Health webinar series provided an in-depth framework for the advantages of including cell and gene therapy coverage in employer health plans, as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results